Abstract
The objective of this paper was to evaluate the cardiovascular risk in white coat hypertension (WCH). WCH is a well-known clinical entity defined by persistently elevated blood pressure (BP) in the doctor's office, whereas BP in other conditions is normal. The prognosis of WCH is unsettled, although two prospective studies that include normal control groups imply that the condition is benign. This study is a 10-year follow-up study on 420 patients with grade I–II hypertension newly diagnosed by their general practitioner and 146 normal controls (NTs). Ambulatory blood pressure (ABP) monitoring was performed at baseline. With our protocollated cutoff value of daytime-ABP <135/90 mmHg, 76 (18.1%) of the 420 hypertensives were white coat hypertensives (WCHs) and 344 were established hypertensives (EHs). With a lower cutoff of 135/85 mmHg, 40 (9.5%) were WCHs. Complete follow-up data were obtained for all 566 subjects. The mean duration of follow-up was 10.2 years (range 9.0–12.5). In the WCH group, 14 first events were recorded (18.4%) consisting of two cardiovascular deaths and 12 nonfatal cardiovascular events. In the EH group, the corresponding number of events were 56 first events (16.3%), 12 cardiovascular deaths and 44 nonfatal cardiovascular events, and in the NT group 10 first events (6.8%), two cardiovascular deaths and eight nonfatal cardiovascular events. The event rate was similar in the WCH group and the EH group and significantly lower in the NT group (P<0.05). When corrected for daytime-ABP, age and other confounders, the difference remained statistically significant. When using the lower cutoff of 135/85 mmHg, WCH was still associated with a significantly higher cardiovascular event rate. In conclusion, the main finding of this 10-year follow-up study is an increased cardiovascular risk in WCH compared to normotensive controls.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pickering TG et al. How common is white coat hypertension? JAMA 1988; 259: 225–228.
Riva-Rocci S . Un nuovo Sfigmomenometro. Gaz Med Torino 1896; 47: 981–996.
Ayman D, Goldshine AD . Blood pressure determinations by patients with essential hypertension. Am J Med Sci 1940; 200: 465–474.
Sokolow M, Werdegar D, Kain HK, Hinman AT . Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 1966; 34: 279–298.
Verdecchia P et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.
Khattar RS, Senior R, Lahiri A . Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998; 98: 1892–1897.
Fagard RH et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation 2000; 102: 1139–1144.
Kario K et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 2001; 38: 238–245.
Hoegholm A, Kristensen KS, Madsen NH, Svendsen TL . White coat hypertension diagnosed by 24-h ambulatory monitoring. Examination of 159 newly diagnosed hypertensive patients. Am J Hypertens 1992; 5: 64–70.
Hoegholm A et al. Left ventricular mass and geometry in patients with established hypertension and white coat hypertension. Am J Hypertens 1993; 6: 282–286.
Hoegholm A et al. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994; 24: 101–105.
Hoegholm A, Kristensen KS, Bang LE, Nielsen JW . White coat hypertension and target organ involvement: the impact of different cut-off levels on albuminuria and left ventricular mass and geometry. J Hum Hypertens 1998; 12: 433–439.
Hoegholm A, Kristensen KS, Bang LE, Gustavsen PH . White coat hypertension and blood pressure variability. Am J Hypertens 1999; 12: 966–972.
Hoegholm A et al. Clinical evaluation of the Takeda Medical (A & D) TM 2420 ambulatory blood pressure monitor. Practical experience and comparison with direct and indirect measurements. Scand J Clin Lab Invest 1992; 52: 261–268.
Verdecchia P et al. Properly defining white coat hypertension. Eur Heart J 2002; 23: 106–109.
Hoegholm A . The clinical significance of white coat hypertension. Thesis, 2000, pp 1–64. Request: hoegholm@dadlnet.dk
Ohkubo T et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998; 32: 255–259.
Perloff D, Sokolow M, Cowan R . The prognostic value of ambulatory blood pressures. JAMA 1983; 249: 2792–2798.
Redon J et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712–718.
Palatini P et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 1992; 152: 1855–1860.
Kristensen KS et al. No impact of blood pressure variability on microalbuminuria and left ventricular geometry: analysis of daytime variation, diurnal variation and ‘white coat’ effect. Blood Press Monit 2001; 6: 125–131.
Rostrup M, Kjeldsen SE, Eide IK . Awareness of hypertension increases blood pressure and sympathetic responses to cold pressor test. Am J Hypertens 1990; 3: 912–917.
Chang NC, Lai ZY, Chan P, Wang TC . Left ventricular filling profiles in young white-coat hypertensive patients without hypertrophy. Hypertension 1997; 30: 746–752.
Weber MA, Neutel JM, Smith DH, Graettinger WF . Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994; 90: 2291–2298.
Pierdomenico SD et al. Low-density lipoprotein oxi-dation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998; 31: 621–626.
Acknowledgements
We thank Hans Ibsen, MD, DMS, for the expert advice. This work was supported by grants from The Danish Heart Foundation, The Danish Medical Association, Emmerik Meyers Legat and Lægekredsforeningen for Storstrøms Amt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gustavsen, P., Høegholm, A., Bang, L. et al. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens 17, 811–817 (2003). https://doi.org/10.1038/sj.jhh.1001643
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001643
Keywords
This article is cited by
-
Labile hypertension: a new disease or a variability phenomenon?
Journal of Human Hypertension (2019)
-
Endothelial function in children with white-coat hypertension
Heart and Vessels (2018)
-
Clinical Implications of Different Blood Pressure Measurement Techniques
Current Hypertension Reports (2017)
-
White Coat Hypertension: to Treat or Not to Treat?
Current Hypertension Reports (2016)
-
Prevalence of white-coat and masked hypertension in national and international registries
Hypertension Research (2015)